

11/14/2019

**Meeting of Luminec Pharmaceuticals with Dr. Susana Alcázar-Leyva
(Dr. Alcázar), held from October 24 to 26, 2019,
in the city of Querétaro, Mexico.**

Through this summary, as the Executive Advisor of Luminec Pharmaceuticals and Executive Director of Luminec Health & Wellness Clinic, SA, I share my experience by personally meeting Dr. Susana Alcázar-Leyva and her therapy.

The company Luminec Pharmaceuticals, has worked with Dr. Alcázar for many years at an international level in a program of GRAS (Generally Recognized as Safe) therapies, for various conditions, with successful results, in combination with Luminec's, Triamio/SK-713 & Tafa400/Sk-713.

Luminec Pharmaceuticals, an integral company, with a therapy at the human and animal level, carried out a review on the products of Professor Heberto Alcázar-Montenegro, which his daughter Dra. Susana Alcázar has been using on her patients for decades. During this review, it became clear that their treatments project an unquestionable and revolutionary potential, which can solve and overcome therapeutic challenges, such as complications of diabetes, viral and bacterial infections, resistant to antibiotics, and cancer by reducing or eliminating tumors and avoiding possible metastases. Various addictions have also been treated.

Dr. Alcázar has published more than 50 articles in national and international journals, and has participated in the publication of several books in her field. In particular, the use of thiamine cocarboxylase or pyrophosphate (PPT) stable in solution, coenzyme whose trade name is X-2, has been the basis of its therapy, for its activity in cell repair. The main achievement of Professor Alcázar-Montenegro, has been to have chosen essential molecules that participate in the metabolism, and to be used as therapy, achieved its stability in solution, it is: coenzymes, enzymes and nucleic acids.

The scientific work of Professor Alcázar-Montenegro and the documents that Dr. Alcázar has published, have been recognized internationally, since this stable cocarboxylase in solution, has proved to be superior to other formulas that are in the market.

During our visit, Dr. Alcazar made a presentation on the mechanism of action of coenzymes, enzymes and nucleic acids, *in vitro*, *in vivo* and at the clinical level. Its main products are: X-2,

CRO-50, DNSM, N-N and RNA, mainly. These products have been used as a single therapy or as an adjuvant with others, as it does not contradict any compound or cause side effects. They have been applied to more than 60,000 patients in Mexico and other parts of the world.

Scientific studies were carried out in several national and international institutions: UNAM, UAM, IPN, CINVESTAV, ECQUC, ESAANUC, UAQ, INER, IN Cardiology, ULSA, INN, CEMIFAR, INB UNAM, WR Grace & Co, Columbia, Maryland, and at HN Bayreuth, Germany. The results have been published in scientific journals and as a professional thesis. The Foundation for Health and Eradication of Incurable Diseases at the Service of Humanity, Chile, 1973; Galepharma, Iberian in 1973; and Hoffman-La Roche, in 1974 were interested in using and/or producing their products.

The mechanism of action is clearly established, and its possibilities are unique, since its compounds have the ability to penetrate and repair damaged cells, which has been documented.

Luminec Pharmaceuticals' mission with its products: TRIAMINO™/SK-713™ and TAFA400™/SK-713™ is to revolutionize *The Future of Healing™*, in combination with Professor Alcázar-Montenegro's therapy, both with efficient therapeutic studies and results.

Luminec Pharmaceuticals will focus on the following conditions:

1. Diabetes: The treatment of X-2, not only prevents the disabling complications of this pathology, but also optimizes cellular energy metabolism, by promoting glucose metabolism, and reducing the dose of oral hypoglycemic agents and/or Insulin in these patients. All known treatments for diabetes available today require the patient to be responsible for eating a proper diet and monitoring their glucose levels. This treatment allows the diabetic patient to recover their homeostasis, at the metabolic and hormonal level, and avoid the complications caused by this condition, which is documented.

2. Cancer treatment: Enzymes or nucleases (ribonuclease, CRO-50, and deoxyribonuclease, DNSM, stable in solution), eliminate damaged, aged and neoplastic cells (abnormal multiplication), regulate the metabolism of nucleic acids, in their hydrolysis and in its synthesis. Other therapeutic effects that both enzymes have are their anti-inflammatory activity, since they eliminate dead or degenerated cells due to oxidative damage, bacteria and viruses in mucus and abscesses, bruises and clots; and antimicrobial, since they inhibit the replication of viruses and pathogenic bacteria. In cancer both enzymes should be used before and after the removal of a tumor; before, during and after chemotherapy, and in the long term to avoid metastasis. In cancer, nucleases are selective, because they only act in malignant cells.

3. Opioid and methamphetamine addiction, including heroin: Heroin, rather than methamphetamine, is considered one of the most challenging addictions. N-N (nicotinamide adenine dinucleotide, NAD, stable in solution), has been successfully used to stop addiction. In less than two weeks of daily dosing, the addicted person rejects the drug, without withdrawal symptoms. This novel approach can be used alone or in combination with other related therapies. Both X-2 and N-N can physically, emotionally and neurologically rehabilitate these patients, recovering their lives.

4. Worldwide application: as clearly stated on the front page of the Luminec Pharmaceuticals website (www.luminecpharmaceuticals.com), our mission is to provide solutions to two current and universally recognized challenges in the healthcare industry: cost and quality of life. Our goal is to favor third world countries with these unique and independent formulas in the form of broad spectrum applications. Luminec Pharmaceuticals intends to take these therapies with low manufacturing cost, to the rest of the world.

Luminec Pharmaceuticals is committed to working with Dr. Alcázar to bring these treatments both in humans and animals, worldwide. In the case of humans with diabetes, liver disease, kidney disease, heart disease, lung disease, and some autoimmune diseases such as: lupus, rheumatoid arthritis, cystic fibrosis and multiple sclerosis. In pathologies of the central nervous system: Parkinson's disease and senile dementia. Also as preventive therapy, in athletes and in stress.

In animals, in case of viral or bacterial infections, inflammatory and tumor processes, since cancer in these species has also increased. In work or cargo animals, tillage, surveillance, guide, sport, company and competition.

This new treatment platform changes the rules of the game, since it is a natural, cost-effective and homeostatic delivery system that acts in damaged cells or in metabolic paralysis when restoring energy in the metabolism, and in those cases where there were no results, and even in newborn babies, without side effects.

X-2, DNSM, CRO-50, NN, RNA, TRIAMINO™/SK-713™ and TAFA400™/SK-713™, and their various combinations with other active ingredients, improve the quality of life of patients and reduce side effects caused by other medications, such as chemotherapy. They are also used as preventive therapy, to prevent pathological aging.

The potential earnings that can be generated in the next 3-5 years may very well exceed hundreds of millions of dollars annually. Here are some evaluations made on some markets:

- The global chemotherapy market was \$ 97 billion in 2017.

- The Evaluate Pharma analysis group calculated oncology sales of \$ 123.8 billion in 2018.

- The US drug abuse market, according to Market Watch, is currently 14.5 billion annually; projected to increase to \$ 20.9 billion in 2024.


- The global market for diabetes therapy was valued at almost \$ 67 billion in 2016 and is projected to reach \$ 167 billion by the year 2023.

The use of prescription and over-the-counter medications developed by Luminec Pharmaceuticals and those of Dr. Alcázar could take approximately one year.

Luminec Pharmaceuticals will position itself as a company at the forefront, achieving results in the face of the challenges and pandemics of our time, through its wide range of effective, safe, and scientifically proven products.

Table and pamphlet on the X-2, CRO-50 and DNSM, used by Dr. Alcázar are attached.

**This document has been edited and approve by Dra. Susana Alcazar.*

 Date 11/16/20
Dr. Juan Funes